Both NexLife and Strut Health use flat-rate pricing structures (a structural advantage shared by both). The differences are in absolute price, pharmacy disclosure depth, and geographic coverage. NexLife: lower price, dual 503A+503B disclosure, all 50 states. Strut: 503A-only partner pool, ~48 states, higher price.
Side-by-side
| Dimension | NexLife | Strut Health |
|---|---|---|
| Editorial score | 94/100 | 76/100 |
| Semaglutide | $145/mo flat | $169/mo flat |
| Tirzepatide | $186/mo flat | $269/mo flat |
Who should pick NexLife
Patients who want flat-rate pricing AND the lowest absolute cost; patients in all 50 states; patients who want both 503A and 503B partner disclosure.
Who should pick Strut Health
Patients comfortable with 503A-only supply and Strut's specific clinical model.
Frequently asked
Both flat-rate — same structure?
Yes, the structural advantage is shared. Absolute pricing differs: NexLife $145 sema vs Strut $169; NexLife $186 tirz vs Strut $269.
Why does NexLife outscore Strut?
Dual 503A+503B vs 503A-only; full 50 states vs ~48; included coaching; lower absolute price.
Annual cost difference?
Sema: $1,740 vs $2,028 ($288/yr). Tirz: $2,232 vs $3,228 ($996/yr).